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Despite great interest, two randomised controlled trials (RCTs) of cytoreductive nephrectomy 
in the tyrosine kinase inhibitor setting in metastatic renal cell carcinoma have either closed 
early (SURTIME) or are recruiting very slowly (CARMENA) after 7 yr. Challenges in RCT 
delivery in uro-oncologic surgery are many. Multiple steps are needed to ensure strong 
recruitment to trials addressing important urologic cancer questions. Feasibility/pilot studies 
are key stepping stones towards successful delivery of surgical RCTs. 
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Renal cancer surgeons are acutely aware of pre-eminent data from the immunotherapy era 
demonstrating a significant survival advantage for patients with metastatic renal cell cancer 
(mRCC) having cytoreductive nephrectomy (CNx) before IFN- treatment [1,2]. However, 
oncologic treatments given to patients with mRCC have radically changed in the current era 
in which pan-tyrosine kinase inhibitors (TKIs) and those specifically targeting VEGF or 
mTOR are used. In 2009/2010 the urological surgery community widely supported the launch 
of two randomised controlled trials that aimed to assess the place of CNx among mRCC 
patients treated with TKIs, as well as the timing of CNx in relation to TKI administration. In 
the French CARMENA trial (NCT00930033), patients were to be randomised to CNx and 
sunitinib versus sunitinib alone without CNx (Supplementary Fig. 1). In the EORTC 
sponsored SURTIME trial (EORTC 30073; NCT01099423), the sequencing of drug and 
surgical therapies was to be assessed. Patients were randomised to sunitinib followed by CNx 
and subsequent sunitinib versus CNx followed by sunitinib (Supplementary Fig. 2). However, 
recruitment to these two studies has been hugely challenging. 
After initial robust recruitment in France, CARMENA was opened to recruitment in the UK 
in May 2011. A total of 26 sites around the UK were opened for CARMENA recruitment. 
However, CARMENA was closed to recruitment in the UK in 2014, as only 14 patients were 
recruited over 4 yr. However, the CARMENA study continues to recruit slowly in France 
(411 of 576 patients recruited) and it is likely to complete recruitment in September 2017; the 
study is estimated to end 6 yr later than originally planned. In an attempt to try and determine 
why this study failed to recruit in a nation with a robust trial infrastructure, an investigator 
questionnaire was sent to the UK investigators. Responses indicated that there was a lack of 
patient and clinician equipoise and an inability of the clinical team to convince patients to be 
*Manuscript
randomised (Table 1). Within the investigator questionnaire, 34 varied mRCC clinical 
scenarios were described, and investigators were asked if they would recommend surgery, 
drug treatment, best supportive care, or entry into CARMENA. Of the 17 respondents (65% 
response rate), the five urologists stated that their preferred management strategy would be 
CARMENA for a median of 20 of the scenarios (range 11–22), whereas the 12 oncologists 
opted for CARMENA for a median of 8.5 scenarios (range 6–19). Thus, urologists appeared 
to have greater levels of equipoise for the study. However, if there is one key individual 
within the clinical team who lacks equipoise, this is usually transferred to the patient, making 
recruitment more challenging. 
The SURTIME study has also been hugely challenging, with poor recruitment in many 
centres. Efforts were made by the European Organisation for Research and Treatment of 
Cancer (EORTC) to improve accrual via online education tools and regular updates. Accrual 
was strongest in the Netherlands and Canada, and best in centres with a main focus on RCC 
management, where study eligibility was discussed at multidisciplinary tumour teams with 
urologists and oncologists together. However, SURTIME eligibility criteria were complex 
and were considered among the main reasons for the poor accrual. This was especially true 
for smaller centres, for which small numbers of patients precluded experience with the entry 
criteria. In addition, although surgery and therapy were offered in both arms, it proved 
difficult to convince patients assent to randomisation. The study closed early in 2016 and is 
probably underpowered to show differences in the primary and secondary endpoints of 
progression-free survival and overall survival, but may answer the question of rapid 
progression after pretreatment and interruption for surgery. 
Therefore, the main hope for level 1 evidence regarding the place of CNx in mRCC in the 
TKI era comes from recruitment to CARMENA study by the French team. However, there 
are some concerns that this study will only answer the question of whether both arms are 
“equivalent”; recruitment of 1134 patients is needed to be able to determine if either arm was 
deleterious. Thus, it may be that lower levels of evidence suggesting that CNx is beneficial in 
selected situations such as patients predicted to have life expectancy of >1 yr are the best we 
will have to answer this common clinical dilemma [3]. It is of concern that there is evidence 
that CNx is now underutilised, especially in non-academic centres and for Black and 
uninsured patients. This underutilisation of CNx was associated with 10-mo poorer mRCC 
survival [4]. 
Recruitment issues in surgical trials are not specific to urology. It has been recognised for a 
number of years that randomised controlled trials (RCTs) in surgery are exceedingly 
challenging for a number of reasons [5,6]: surgeon and patient equipoise; perceived threats to 
the surgeon’s personal interests; lack of funding, infrastructure, and experience in data 
collection; operative learning curves; and blinding. A recent study revealed that one in five 
surgical RCTs were stopped early, and one in three completed trials did not publish after a 
median of 4.9 yr [7]. The commonest reason for discontinuation was, as in the SURTIME 
example, poor recruitment. Numerous initiatives to improve recruitment to surgical RCTs 
have been attempted and are currently ongoing to improve renal cancer surgery trials, but it is 
clear that there is no single solution that will improve the situation (Table 2). Thus, in 
addition to the multiple sensible measures to improve recruitment once a trial has opened, it 
is now recommended that for any renal cancer surgery–related RCT, a feasibility or pilot 
study in a limited number of patients and centres be instigated before launching the main 
trial. Results from successful feasibility/pilot studies will allow the launch of a fully powered 
study, may influence the power calculation for the full study, and could provide a cadre of 
engaged urologists to deliver future clinical trials. 
There are signs that in surgery in general the tide is changing in terms of delivery of 
successful RCTs [8]. Despite this, as we move into the second generation of the RCC 
immunotherapy, it is likely that we will never answer the question of the place of CNx in 
patients treated with TKIs. 
 
 
Conflicts of interest: Alain Ravaud and Arnaud Méjean are co-Chief Investigators of 
CARMENA. Michael Aitchison was the UK lead investigator for CARMENA. Axel Bex is 
the co-Chief Investigator for SURTIME. The remaining other authors have nothing to 
disclose.t 
 
Acknowledgments: CARMENA is sponsored by Assistance Publique-Hôpitaux de Paris 
(APHP). CARMENA-UK was funded by Cancer Research UK and administered by the 
CRUK Clinical Trials Unit, The Beatson West of Scotland Cancer Centre, Glasgow. 
SURTIME was sponsored by the European Organisation for Research and Treatment of 
Cancer (EORTC). 
 
 
References 
[1] Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon 
alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J 
Med 2001;345:1655–9. 
[2] Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R, European Organisation 
for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical 
nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa 
alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358:966–70. 
[3] Heng DYC, Wells JC, Rini BI, et al. Cytoreductive nephrectomy in patients with 
synchronous metastases from renal cell carcinoma: results from the International 
Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol 2014;66:704–10. 
[4] Hanna N, Sun M, Meyer CP, et al. Survival analyses of metastatic renal cancer patients 
treated with targeted therapy with or without cytoreductive nephrectomy: a National 
Cancer Data Base study. J Clin Oncol. In press. 
http://dx.doi.org/10.1200/JCO.2016.66.7931 
[5] Horton R. Surgical research or comic opera: questions, but few answers. Lancet 
1996;347:984–5. 
[6] McCulloch P, Taylor I, Sasako M, Lovett B, Griffin D. Randomised trials in surgery: 
problems and possible solutions. Br Med J 2002;324:1448–51. 
[7] Chapman SJ, Shelton B, Mahmood H, Fitzgerald JE, Harrison EM, Bhangu A. 
Discontinuation and non-publication of surgical randomised controlled trials: 
observational study. Br Med J 2014;349:g6870. 
[8] Editorial. The struggle for better research in surgery. Lancet 2016;387:1970. 
 
Table 1 – Selection of quotes in response to the investigator questionnaire that illustrate 
the lack of clinician and patient equipoise 
“Randomisation is difficult and if offered surgery as a possible treatment, most patients decided to have it off 
trial.” 
“Relatively few patients with clinical equipoise.” 
“Patient choice was our main failure.” 
“Patients unwilling to be randomised between surgical and nonsurgical option. Patients often have strong views 
as to whether they would want to undergo surgery or not in a palliative setting.” 
“There was rarely equipoise at MDT discussion” 
“Unwillingness to recruit due to surgeon/oncology bias.” 
“Many patients I saw either ‘obviously’ needed a nephrectomy or ‘obviously’ needed oncology. I did not want 
to delay their treatment.” 
MDT = multidisciplinary team. 
 
 
 
Table 2 – Recommendations for future surgery-related randomised controlled trials 
Canvassing of the speciality regarding key questions for clinical trials (eg, using Delphi process) 
Iterative discussion process with NCRI Clinical Studies Group during development 
Initial pilot or feasibility study (refine recruitment procedures and inform recruiter training by piloting 
recruitment materials and determining reason for screening failures) 
Consider a clinical nurse specialist to provide information in an unbiased manner with enough time for full 
discussion 
Confirm commitment and explicitly make the case for equipoise with potential investigators at each site via an 
interview process 
Education and training programme for recruiters 
Ensure a clear reward process (authorship rights, research nurse funding) for high recruiters 
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Supplementary Fig. 1 – Schema of the CARMENA trial. 
 
 
 
 
 
 
 
Supplementary Fig. 2 – Schema of the SURTIME trial. mRCC = metastatic renal cell 
carcinoma; PFS = progression-free survival; OS = overall survival. 
 
APPENDIX III: Study flow chart 
 
ANTI-ANGIOGENIQUE
t)
NEPH IE ANTI-ANGIOGE EUL
(ds
consentement)
CA
(ds les 3 à 6 sem ap le néphrectomie)
FIN DU SUIVI
(au maximum 24 mois ap l'inclusion du dernier patien
J0: RANDOMISATION INFORMATISÉE
RECTOM
(ds les 28J ap la randomisation)
NIQUE S
 les 21J ap la randomisation)
INCLUSION (Délai<28J)
(vérification des critères d'elligibilité et signature du 
NCER DU REIN METASTATIQUE
ANTIANGIOGENIC 
(in the 3 to 6wks following nephrectomy)
END OF FOLLOW UP 
(a maxi um of 24 months after enrolment of last patient)
Arm B 
Antiangiogenic Alone (Sunitinib) 
(within 21 days of randomisation)  
Arm A 
Nephrectomy plus Antiangi genic  
Day 0: COMPUTERISED RANDOMISATION
Metastatic Clear Cell Renal Carcinoma 
SCREE ING Timeframe 28 Days) 
(verification of eligibility criteria and signature of cons nt form) 
 
Supplementary Figures
EURUROL-D-16-01486 
 
Title: Cytoreductive nephrectomy in the tyrosine kinase inhibitor era: a question that may 
never be answered   
 
Revision notes (our response to reviewers’ comments in italics) 
 
Reviewer #1: Well written, informative, with insider information about the status of these 
highly anticipated trials. 
 
Thank you 
 
Reviewer #2: Excellent piece by prominent key opinion leaders in RCC and clinical trials 
about CARMEN and SURTIME.  
 
It is unfortunate that important RCTs are not accruing as well. Many reasons were cited, all 
valid. Would suggest to have references for each one (e.g. surgeon and patient equipoise, 
personal prestige, lack of funding, infrastructure and experience in data collection, 
operative learning curves, and blinding). I also suggest adding role of academic/cooperative 
groups vs. industry trials. Will accrual and finishing trials be more successful with industry-
surgical trials?. Would also suggest to expand on "personal prestige" as this is not a specific 
term. Perhaps the authors meant "personal agenda, personal opinion, personal interest, 
etc..." 
 
Thank you.  
 
The potential reasons for difficulties in recruiting to surgical trials are described in the 
referenced BMJ paper (McCulloch P, Taylor I, Sasako M, Lovett B, Griffin D. Randomised 
trials in surgery: problems and possible solutions. BMJ 2002;324:1448–51). This reference is 
given on line 86.  
 
We have not see any difference in trial accrual and completion based on being an academic 
or industrial study, the completed adjuvant studies ASSURE (academic studies: ECOG/ACRIN) 
and S-TRAC (industrial study: Pfizer) are examples of this assumption.  Co-operation between 
urologist and oncologist is the most important factor and not if lead by industry or academic 
institution. As this is not something we can robustly evidence, we thank the reviewer but 
would prefer not to include this discussion in the manuscript.  
 
We have altered the confusing term ‘personal prestige’ to a more descriptive term ‘perceived 
threat to surgeon’s personal interests’ on line 87. 
 
 
Reviewer #3: Well-written, very interesting including from a surgeon's standpoint. 
 
Thank you 
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Reviewer #4: Well done editorial piece that summarizes the status of cytoreductive surgery 
in the era of targeted therapy.  Could use a bit of editing for better English. 
 
Thank you 
 
Reviewer #5:  Nicely put together editorial.  Two minor suggestions: 
 
-No line numbers are provided on the submission, in accordance with European Urology 
guidelines 
-In the first sentence, the use of "IL-2" is somewhat confusing, as the randomized trials the 
authors are referencing were conducted among patients treated with IFN-alpha. 
 
Continuous line numbers have been inserted  
 
Thank you for identifying the error regarding intermixing of IL-2 and IFN-a. We have 
removed reference to IL-2 and restructured sentence 1 in lines 25-28.  
